Cartesian Therapeutics Q2 net income steady

Cartesian Therapeutics

06/08/2026 12:44

Overview
US cell therapy developer's Q2 net income was nearly flat yr/yr at $15.8 mln
Operating expenses rose yr/yr, mainly due to increased Phase 3 AURORA trial costs
Company secured up to $150 mln in non-dilutive financing, extending cash runway into 2028

Outlook
Company expects Phase 3 AURORA trial data in myasthenia gravis in 1Q27
Cartesian expects Phase 1 in vivo MG trial with WestGene to initiate in 2H26, data in 1H27
Company anticipates current cash resources will support operations into 2028

Result Drivers
R&D SPENDING - Higher research and development expenses were mainly due to increased costs for the ongoing Phase 3 AURORA trial
PIPELINE EXPANSION - New strategic partnership with WestGene aimed at accelerating development of in vivo CAR-T platform and expanding pipeline
CASH RUNWAY EXTENSION - Non-dilutive financing secured, extending cash runway into 2028 and supporting investment in clinical and precommercial activities

Company press release: ID:nGNX78BLF3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$15.77 mln
 
Q2 Operating Expenses
 
$29.16 mln
 
Q2 Operating Income
 
-$29.16 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cartesian Therapeutics, Inc. is $39.00, about 367.1% above its August 5 closing price of $8.35

Reuters Recommended Reads
Aug 5 - Adicet Bio Q2 net loss narrows
Aug 4 - Precigen posts quarterly profit as PAPZIMEOS sales surge
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)